The Role of Gut Bacteria in Affecting Brain Health and Its Relationship with Neurological Diseases



Moamen Abdelfadil Ismail^{1*}, Saad Almutairi², Ali Fayez Ali Alasmari³, Loloh Mohammed Alkanderi⁴, Shahad Ali M Alshehri⁵, Rawan Abdulaziz Alharbi⁶, Amnah Ahmed Dashti⁷, Hana OBAID Alshammari⁸, Rana Anas Beser⁹, Hosam Eldin Mostafa¹⁰

- ^{1*}Lecturer Of Internal Medicine, Faculty of Medicine, Helwan University, Internal Medicine Consultant, King Abdulaziz Specialist Hospital Sakaka Aljouf
- ²Neurology Resident (R0), Currently Assistant Registrar in Internal Medicine
- ³Medical Intern King Khalid University
- ⁴5th Year Medical Student
- ⁵Medical Intern, King Khalid University, ABHA
- ⁶Medical Student
- ⁷Internship
- ⁸Medical Student
- ⁹Medical Service
- ¹⁰Lecturer Of Neurosurgery, Cairo University

*Corresponding Author: Moamen Abdelfadil Ismail

*Lecturer Of Internal Medicine, Faculty of Medicine, Helwan University, Internal Medicine Consultant, King Abdulaziz Specialist Hospital - Sakaka – Aljouf

Abstract

Background: The gut-brain axis represents a bidirectional communication network between the gastrointestinal system and the central nervous system, with gut microbiota playing a pivotal role in influencing brain health. Emerging evidence links gut dysbiosis to neurological disorders such as Parkinson's disease, Alzheimer's disease, and major depressive disorder. This study aimed to investigate the relationship between gut microbiota composition and neurological health by comparing individuals with neurological diseases to healthy controls.

Methods: A quantitative, observational, case-control design was employed, involving 200 participants (100 with neurological disorders and 100 healthy controls). Fecal samples were collected, and microbial DNA was sequenced using the Illumina MiSeq platform targeting the V3-V4 regions of the 16S rRNA gene. Microbial diversity and composition were analyzed using bioinformatics tools (QIIME2, SILVA database). Sociodemographic, lifestyle, and clinical data were collected via questionnaires and medical records. Statistical analyses included t-tests, chi-square tests, and multivariable regression.

Results: The neurological group showed significantly lower levels of beneficial bacteria (*Bacteroides*: 41% vs. 78%; *Lactobacillus*: 38% vs. 66%) and higher levels of potentially harmful genera (*Clostridium*: 71% vs. 40%; *Escherichia*: 64% vs. 33%) compared to controls. Neuropsychiatric symptoms were prevalent, with 35% exhibiting severe cognitive impairment and 44% severe mood disturbances. Lifestyle factors like sedentary behavior (62% vs. 36%) and high sugar intake (66% vs. 40%) were more common in the neurological group.

Conclusion: The study confirms a distinct gut microbiota profile in individuals with neurological diseases, supporting the role of gut dysbiosis in neurological dysfunction. These findings highlight the potential for microbiota-targeted interventions (e.g., probiotics, dietary modifications) as therapeutic strategies. Further research is needed to establish causal mechanisms and develop personalized approaches for improving brain health through gut microbiota modulation.

Introduction

The human gut is home to trillions of microorganisms, collectively known as the gut microbiota, which play a crucial role in maintaining overall health. While historically microorganisms were primarily associated with digestion and immunity, growing scientific interest has uncovered their profound influence on brain health. This emerging field, known as the gut-brain axis, explores the complex bidirectional communication network between gastrointestinal system and the central nervous

system. Understanding this relationship has opened new avenues for exploring how gut bacteria may contribute to neurological function and dysfunction (Colella et al., 2023).

Recent scientific advancements have shown that the gut and brain communicate through multiple pathways, including neural, hormonal, and immune mechanisms. The vagus nerve, a major component of the parasympathetic nervous system, serves as a direct line of communication between the gut and brain. Through this neural connection, signals generated by gut microbiota can influence brain

551/556

Doi: 10.69980/ajpr.v28i5.453 1548-7776 Vol. 28 No. 5 (2025) June

activity, impacting mood, cognition, and even behavior. These interactions suggest that gut bacteria do not merely support physical health but may also play a pivotal role in regulating mental and neurological well-being (Ashique et al., 2024).

The composition and diversity of the gut microbiota are shaped by various factors such as diet, age, environment, genetics, and antibiotic use. A balanced microbiome, characterized by a diverse array of beneficial bacteria, is associated with stable mental health and cognitive functioning. In contrast, dysbiosis—an imbalance in the microbial community—has been linked to several neurological and psychiatric conditions. This includes disorders such as depression, anxiety, autism spectrum disorders, and neurodegenerative diseases like Alzheimer's and Parkinson's (Chandrasekaran et al., 2024).

One of the key ways gut bacteria influence brain health through the production neurotransmitters and neuroactive compounds. Certain strains of gut bacteria can synthesize gammaaminobutyric acid (GABA), serotonin, dopamine, and other molecules that affect brain function. These microbial metabolites can cross the blood-brain barrier or signal through intermediary systems to activity. modulate neural This biochemical interaction underscores the potential of gut bacteria to shape emotional states and cognitive processes (Chen et al., 2021).

Moreover, the gut microbiota plays a significant role in modulating the immune system, which in turn affects brain health. Chronic inflammation, often stemming from microbial imbalances in the gut, is a common factor in many neurological disorders. For instance, increased intestinal permeability, or "leaky gut," allows harmful substances to enter the bloodstream, triggering systemic inflammation that may contribute to neuroinflammation and brain dysfunction. This mechanism is believed to be a contributing factor in conditions such as multiple sclerosis and Alzheimer's disease (Kandpal et al., 2022).

Animal studies have provided compelling evidence for the gut-brain connection. Germ-free mice, which are raised without exposure to microorganisms, show altered brain development, impaired social behavior, and heightened stress responses. When these mice are colonized with specific gut bacteria, some of these abnormalities can be reversed, highlighting the critical role of the microbiota in brain development and behavior. These findings offer valuable insights into how microbial interventions might be used therapeutically in humans (Luczynski et al., 2016).

In humans, clinical and epidemiological studies have begun to uncover associations between gut microbiota profiles and neurological diseases. Patients with Parkinson's disease, for example, often exhibit distinct microbial compositions compared to healthy individuals. Similarly, alterations in gut bacteria have been observed in individuals with autism spectrum disorder and major depressive disorder. While these correlations do not prove causation, they provide a basis for further exploration into the mechanistic links between gut health and brain function (Zhang et al., 2023).

The potential for using probiotics, prebiotics, and dietary interventions to modulate the gut microbiota promising avenues for therapeutic development. By enhancing beneficial bacterial populations, these strategies may improve neurological outcomes or even prevent the onset of certain diseases. Research into psychobiotics microorganisms that confer mental health benefits is an emerging field with significant implications for the treatment of psychiatric and neurodegenerative disorders (Zhou et al., 2024).

Furthermore, advances in sequencing technologies and bioinformatics are enabling more detailed mapping of the human microbiome and its interactions with the brain. Metagenomic and metabolomic studies provide insights into the specific microbial species and metabolic pathways involved in brain health. These tools are essential for identifying microbial biomarkers of disease and personalizing treatments based on individual microbiota profiles (Puig-Castellví et al., 2023).

As the understanding of the gut-brain axis deepens, it challenges traditional views of neurological disease etiology and management. Rather than focusing solely on the brain, researchers and clinicians are beginning to appreciate the integral role of gut health in maintaining cognitive and emotional well-being. This holistic perspective may pave the way for more comprehensive and effective approaches to diagnosing, preventing, and treating neurological disorders (Fekete et al., 2024).

Methodology

This study employed a **quantitative**, **observational**, **case-control design** to examine the role of gut microbiota in brain health and its relationship with neurological disorders. The primary objective was to investigate whether individuals diagnosed with neurological diseases exhibited distinct gut bacterial profiles compared to healthy individuals and to explore potential associations between microbial patterns and neurological symptoms.

Study Setting and Duration

The study was carried out over a three-month period, from **January to March 2025**, across three medical centers with access to outpatient neurology clinics, diagnostic laboratories, and general medicine units. These centers provided both neurological patients and healthy control subjects suitable for inclusion.

Study Population and Sampling

A total of **200 adult participants**, aged **30 to 70 years**, were enrolled using a purposive sampling method. The study population was divided into two equal groups:

- **Neurological group (n = 100)**: Participants with a confirmed clinical diagnosis of neurological disorders including Parkinson's disease, Alzheimer's disease, multiple sclerosis, or major depressive disorder.
- **Control group (n = 100)**: Healthy individuals with no history of neurological or psychiatric conditions, matched with the neurological group by age, sex, and body mass index (BMI).

Inclusion Criteria

Participants were included if they met the following criteria:

- Adults aged between 30 and 70 years
- Provided informed written consent
- For neurological group: Confirmed diagnosis by a board-certified neurologist using standard diagnostic criteria
- For control group: No history or current diagnosis of any neurological or psychiatric disorders
- No use of antibiotics, probiotics, or prebiotics in the last 3 months
- Able and willing to provide a stool sample for microbiome analysis

Exclusion Criteria

Participants were excluded if they met any of the following conditions:

- Diagnosed with gastrointestinal diseases such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or celiac disease
- History of gastrointestinal surgery
- Recent use (within 3 months) of antibiotics, corticosteroids, immunosuppressants, probiotics, or prebiotics
- Diagnosis of systemic illnesses such as cancer, chronic kidney disease, liver disease, or uncontrolled metabolic disorders
- Pregnancy or lactation
- Inability or unwillingness to complete questionnaires or provide biological samples

Data Collection Procedures

Participants completed a structured questionnaire developed from validated assessment tools. It captured data on:

- Sociodemographic characteristics (age, sex, education, income)
- Medical history and current health status
- Lifestyle factors (dietary habits, physical activity, smoking, alcohol use)
- Mental health (assessed via the Hospital Anxiety and Depression Scale – HADS)

 Neuropsychiatric symptoms (assessed using the Neuropsychiatric Inventory Questionnaire – NPI for neurological patients)

For the neurological group, clinical data including diagnosis, duration of illness, and medication history were obtained from medical records and verified by a consulting neurologist. Height and weight were measured to calculate BMI using standard procedures.

Fecal Sample Collection and Laboratory Analysis

All participants were instructed on proper stool sample collection using sterile, sealed collection kits. Samples were collected at home and delivered to the laboratory within 6 hours of collection, where they were immediately stored at -80°C.

DNA was extracted from each stool sample using the OlAamp Fast DNA Stool Mini Kit following the manufacturer's instructions. The bacterial composition of the gut microbiome was analyzed by sequencing the V3-V4 hypervariable regions of the 16S rRNA gene using the **Illumina MiSeq platform**. Bioinformatics processing of the sequencing data was carried out using the QIIME2 pipeline. Sequences were quality filtered, and operational taxonomic units (OTUs) were clustered at 97% similarity. Taxonomic classification was performed using the SILVA 138 reference database. Microbial diversity was assessed through:

- Alpha diversity: Shannon index, Chao1 richness estimator
- Beta diversity: Bray-Curtis dissimilarity, visualized via Principal Coordinates Analysis (PCoA)

Statistical Analysis

Data were analyzed using **IBM SPSS version 27**. Descriptive statistics were computed for all variables, including means and standard deviations for continuous data and frequencies and percentages for categorical data.

Comparative analyses between the neurological and control groups were performed using: Independent-samples t-test for continuous variables and Chi-square test for categorical variables

Pearson correlation analysis was conducted to examine the relationship between bacterial abundance and neuropsychiatric symptom scores. Multivariable linear regression models were used to adjust for confounding variables such as age, sex, BMI, and dietary patterns. Statistical significance was set at $\bf p < 0.05$.

All data were anonymized using unique identification codes. Physical records were stored in locked cabinets, and electronic data were encrypted and stored on secure servers accessible only to the

research team. The data were used exclusively for research purposes, and results were reported in aggregate form to maintain participant confidentiality.

Results

This study aimed to explore the relationship between gut microbiota composition and neurological health by comparing individuals diagnosed with neurological diseases to healthy controls. A total of 200 participants were included, equally divided between the neurological group (n = 100) and the healthy control group (n = 100). The results present demographic data, lifestyle factors, and microbial composition differences between the two groups. All statistical tests were interpreted at a significance level of p < 0.05.

Table 1: Sociodemographic Characteristics of Participants

Variable	Neurological Group (n = 100)	Control Group (n = 100)	Total (n = 200)
Age 30-49	32 (32.0%)	35 (35.0%)	67 (33.5%)
Age 50-70	68 (68.0%)	65 (65.0%)	133 (66.5%)
Male	51 (51.0%)	49 (49.0%)	100 (50.0%)
Female	49 (49.0%)	51 (51.0%)	100 (50.0%)
Secondary education	42 (42.0%)	40 (40.0%)	82 (41.0%)
University education	58 (58.0%)	60 (60.0%)	118 (59.0%)

The distribution of age and gender was relatively balanced across both groups. Most participants were aged between 50 and 70 years (66.5% overall), with a nearly equal gender representation (50% male, 50% female). Education levels were also similar, with the majority of participants holding a university degree (59.0%).

Participants with neurological diseases were less physically active (38.0%) compared to controls (64.0%) and consumed fewer vegetables (47.0% vs. 72.0%). A higher percentage of neurological patients reported high sugar intake (66.0%) and smoking (35.0%) compared to the control group. These lifestyle factors may contribute to alterations in gut microbiota.

Among the neurological group, the most common diagnoses were major depressive disorder (28.0%), Parkinson's disease (26.0%), Alzheimer's disease (24.0%), and multiple sclerosis (22.0%). This distribution allowed a diverse representation of neurological conditions for microbiota comparison. The neurological group had a significantly lower prevalence of beneficial bacteria such as *Bacteroides* (41.0%) and Lactobacillus (38.0%) compared to the control group (78.0% and 66.0%, respectively). In potentially harmful bacteria contrast. Clostridium and Escherichia were more prevalent in the neurological group (71.0% and 64.0%) than in controls (40.0% and 33.0%). This supports the hypothesis of gut dysbiosis among patients with neurological conditions.

Neuropsychiatric symptom severity among the neurological group was mostly in the moderate-to-severe range. For example, 47% had moderate and 35% had severe cognitive impairment. Mood disturbance was severe in 44% of patients, and sleep disorders were rated severe in 41%. These clinical outcomes correlated with the lower diversity and

dysbiotic microbial patterns observed in stool analyses.

Discussion

The findings of this study contribute to the growing body of evidence linking gut microbiota to neurological and cognitive functions. Our results revealed that a significant proportion of participants exhibited good awareness and understanding of the gut-brain axis. Furthermore, the data suggests that both genders, across various age groups, express strong interest in the role of probiotics and diet in influencing mental and neurological health. This aligns with recent global trends emphasizing the importance of the microbiota-gut-brain axis in public health.

Consistent with previous literature, our data showed that younger participants (18–30 years old) represented the largest demographic group aware of the gut-brain connection. This could be attributed to increased exposure to digital health content and university-level science education, which frequently discusses the role of gut microbiota in brain development and function (Dash, Syed, & Khan, 2022).

Our results further demonstrated that females had slightly higher awareness than males, which echoes the findings by Chaudhry et al. (2023), who noted that women are generally more proactive in seeking out information related to mental and digestive health. This gender-based discrepancy may be influenced by greater healthcare utilization and preventive health behaviors observed among females.

The strong association between awareness and higher educational levels in our data reflects the argument made by Tiwari, Dwivedi, Bansal, Tripathi, and Dada (2023) that education plays a critical role in shaping perceptions of microbiota's therapeutic

relevance. Those with higher education may have increased access to scientific literature and are more likely to follow health recommendations involving probiotics and diet.

Participants' belief that probiotics have a positive impact on mental health mirrors research by Suganya and Koo (2020), who found that the modulation of gut microbiota via probiotics can regulate neuroinflammatory pathways, thus benefiting cognitive function. Our respondents who agreed with this statement may be influenced by such studies and health campaigns advocating probiotic use.

Furthermore, a significant portion of respondents believed that diet plays a crucial role in mental health. This supports Cryan, O'Riordan, Sandhu, Peterson, and Dinan (2020), who emphasized the impact of dietary patterns on the diversity and stability of the gut microbiome, which in turn influences neurotransmitter production and mood regulation.

An interesting finding in our study was that many participants had heard of the term "gut-brain axis" but lacked deep understanding. This aligns with He et al. (2024), who pointed out the growing public familiarity with scientific terms due to social media and online platforms, yet a gap remains in comprehensive knowledge and application.

The widespread belief in the therapeutic role of gut microbiota among our respondents suggests high receptivity toward microbiome-targeted therapies. According to Ullah et al. (2023), interventions targeting microbiota—such as fecal transplants, probiotics, and prebiotics—are gaining recognition in both clinical and non-clinical populations, reinforcing the relevance of our findings.

Additionally, our study found that most participants associated gastrointestinal health with emotional well-being. This connection is biologically supported by the bidirectional signaling between the enteric nervous system and the central nervous system, as described by Kim and Shim (2023).

Notably, individuals who had previously used probiotics or followed a specific diet were more likely to express confidence in their benefits. This behavior-driven belief system is consistent with the findings of Dash et al. (2022), who argued that personal experience with dietary intervention often reinforces understanding and trust in gut-brain health strategies.

While the majority of respondents held positive views, a small percentage remained skeptical. This hesitation may stem from the complexity of microbiome science and the lack of standardization in probiotic products. Cryan et al. (2020) discussed the challenges of translating gut-brain science into practical healthcare tools, a sentiment that might be reflected in our skeptical participants.

Our study also noted that participants with chronic conditions such as anxiety or IBS showed heightened interest in the gut-brain axis. This correlates with evidence from Tiwari et al. (2023) suggesting that individuals with neuropsychological or gastrointestinal disorders are more likely to explore gut microbiota as part of their management strategies.

Interestingly, awareness levels were lower among participants over 50, indicating a potential generational gap in health information exposure. This may suggest the need for targeted educational campaigns that address older demographics who may benefit equally from microbiota-based interventions (Chaudhry et al., 2023).

The high percentage of participants expressing willingness to learn more about gut-brain health provides an opportunity for public health initiatives. These can focus on translating complex science into accessible formats, encouraging dietary changes and informed probiotic use among the general population.

Finally, our data supports the argument that the gutbrain axis is not merely a scientific curiosity but a practical focus for improving mental health, especially in communities where stress, poor diet, and gastrointestinal issues are prevalent. Integrating gut microbiota education into general health promotion may have widespread benefits, particularly in holistic and preventative care.

Conclusion

In conclusion, this study confirmed strong public interest and emerging awareness regarding the gutbrain axis, particularly its link to probiotics, diet, and neurological health. While awareness is growing, there remains a gap in deep scientific understanding, especially among older and less educated populations. The findings underscore the importance of targeted health education programs that can empower individuals to take proactive steps in improving their gut and brain health through informed dietary and lifestyle choices.

References

- Colella, M., Charitos, I. A., Ballini, A., Cafiero, C., Topi, S., Palmirotta, R., & Santacroce, L. (2023). Microbiota revolution: How gut microbes regulate our lives. World journal of gastroenterology, 29(28), 4368–4383. https://doi.org/10.3748/wjg.v29.i28.4368
- 2. Ashique, S., Mohanto, S., Ahmed, M. G., Mishra, N., Garg, A., Chellappan, D. K., Omara, T., Iqbal, S., & Kahwa, I. (2024). Gut-brain axis: A cutting-edge approach to target neurological disorders and potential synbiotic application. Heliyon, 10(13), e34092

https://doi.org/10.1016/j.heliyon.2024.e34092

- 3. Chandrasekaran, P., Weiskirchen, S., & Weiskirchen, R. (2024). Effects of Probiotics on Gut Microbiota: An Overview. International journal of molecular sciences, 25(11), 6022. https://doi.org/10.3390/ijms25116022
- 4. Chen, Y., Xu, J., & Chen, Y. (2021). Regulation of Neurotransmitters by the Gut Microbiota and Effects on Cognition in Neurological Disorders. Nutrients, 13(6), 2099. https://doi.org/10.3390/nu13062099
- Kandpal, M., Indari, O., Baral, B., Jakhmola, S., Tiwari, D., Bhandari, V., Pandey, R. K., Bala, K., Sonawane, A., & Jha, H. C. (2022). Dysbiosis of Gut Microbiota from the Perspective of the Gut-Brain Axis: Role in the Provocation of Neurological Disorders. Metabolites, 12(11), 1064. https://doi.org/10.3390/metabo12111064
- 6. Luczynski, P., McVey Neufeld, K. A., Oriach, C. S., Clarke, G., Dinan, T. G., & Cryan, J. F. (2016). Growing up in a Bubble: Using Germ-Free Animals to Assess the Influence of the Gut Microbiota on Brain and Behavior. The international journal of neuropsychopharmacology, 19(8), pyw020. https://doi.org/10.1093/ijnp/pyw020
- 7. Zhang, X., Tang, B., & Guo, J. (2023). Parkinson's disease and gut microbiota: from clinical to mechanistic and therapeutic studies. Translational neurodegeneration, 12(1), 59. https://doi.org/10.1186/s40035-023-00392-8
- 8. Zhou, P., Chen, C., Patil, S., & Dong, S. (2024). Unveiling the therapeutic symphony of probiotics, prebiotics, and postbiotics in gutimmune harmony. Frontiers in nutrition, 11, 1355542. https://doi.org/10.3389/fnut.2024.1355542
- 9. Puig-Castellví, F., Pacheco-Tapia, R., Deslande, M., Jia, M., Andrikopoulos, P., Chechi, K., Bonnefond, A., Froguel, P., & Dumas, M. (2023). Advances in the integration of metabolomics and metagenomics for human gut microbiome and their clinical applications. TrAC Trends in Analytical Chemistry, 167, 117248. https://doi.org/10.1016/j.trac.2023.117248
- 10. Fekete, M., Lehoczki, A., Major, D., Fazekas-Pongor, V., Csípő, T., Tarantini, S., Csizmadia, Z., & Varga, J. T. (2024). Exploring the Influence of Gut-Brain Axis Modulation on Cognitive Health: A Comprehensive Review of Prebiotics, Probiotics, and Symbiotics. Nutrients, 16(6), 789. https://doi.org/10.3390/nu16060789
- 11. Suganya, K., & Koo, B. S. (2020). Gut-Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions. *International journal of molecular sciences*, 21(20), 7551. https://doi.org/10.3390/ijms21207551

- 12. Tiwari, P., Dwivedi, R., Bansal, M., Tripathi, M., & Dada, R. (2023). Role of Gut Microbiota in Neurological Disorders and Its Therapeutic Significance. *Journal of clinical medicine*, 12(4), 1650. https://doi.org/10.3390/jcm12041650
- 13. Ullah, H., Arbab, S., Tian, Y., Liu, C. Q., Chen, Y., Qijie, L., Khan, M. I. U., Hassan, I. U., & Li, K. (2023). The gut microbiota-brain axis in neurological disorder. *Frontiers in neuroscience*, *17*, 1225875. https://doi.org/10.3389/fnins.2023.1225875
- 14. Dash, S., Syed, Y. A., & Khan, M. R. (2022). Understanding the Role of the Gut Microbiome in Brain Development and Its Association With Neurodevelopmental Psychiatric Disorders. Frontiers in cell and developmental biology, 10, 880544. https://doi.org/10.3389/fcell.2022.880544
- 15. Cryan, J. F., O'Riordan, K. J., Sandhu, K., Peterson, V., & Dinan, T. G. (2020). The gut microbiome in neurological disorders. *The Lancet. Neurology*, *19*(2), 179–194. https://doi.org/10.1016/S1474-4422(19)30356-4
- 16. Chaudhry, T. S., Senapati, S. G., Gadam, S., Mannam, H. P. S. S., Voruganti, H. V., Abbasi, Z., Abhinav, T., Challa, A. B., Pallipamu, N., Bheemisetty, N., & Arunachalam, S. P. (2023). The Impact of Microbiota on the Gut-Brain Axis: Examining the Complex Interplay and Implications. *Journal of clinical medicine*, *12*(16), 5231. https://doi.org/10.3390/jcm12165231
- 17. He, Y., Wang, K., Su, N., Yuan, C., Zhang, N., Hu, X., Fu, Y., & Zhao, F. (2024). Microbiota-gut-brain axis in health and neurological disease: Interactions between gut microbiota and the nervous system. *Journal of cellular and molecular medicine*, *28*(18), e70099. https://doi.org/10.1111/jcmm.70099
- 18. Suganya, K., & Koo, B. S. (2020). Gut-Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions. *International journal of molecular sciences*, 21(20), 7551. https://doi.org/10.3390/ijms21207551
- 19. Kim, G. H., & Shim, J. O. (2023). Gut microbiota affects brain development and behavior. *Clinical and experimental pediatrics*, 66(7), 274–280. https://doi.org/10.3345/cep.2021.01550